Cervical Cancer Prevention


Most people who become infected with HPV will not have any symptoms and will clear the infection on their own.  But, some of these viruses are called "high-risk" types.

HPV is the most common sexually transmitted infection in the United States.  The highest infection rate occurs in adolescents and young adults.

Gardasil is a new vaccine recommended for routine immunization for 11-12 year old girls.  This recommendation's rationale is that the vaccine will have the greatest impact when given before girls are sexually active.  Although the vaccine is very effective in preventing infection with the types of HPV included in the vaccine, it appears to have no effect on the outcome of an HPV infection already in progress.

HPV vaccine is also recommended for older girls who have not been previously vaccinated, even if sexually active.

Gardasil is recommended as part of a comprehensive program for the long-term health of adolescent and young adult females and as a means to prevent cervical cancer (Retrieved from the American Academy of Pediatrics, 2008).

Gardasil is available through your child's primary care physician, Winnebago County Health Department, and through South Beloit Health Center (1-815-389-9252).


For the CDC Fact Sheet on Genital HPV Infections, click the following:



For the American Academy of Pediatrics website, click the following:


Title Hide Details 
1/09/12 > New Pediatric Acetaminophen Dosing Guidelines and Formulation
Because there has been numerous dosing errors with pediatric acetaminophen products, such as Tylenol TM, Little Fevers TM, the FDA has made recommendations for proposed changes that may be implemented soon. 1. Newer guidelines will include dosage recommendations for ages 6 months to 2 years. 2. Newer dosing recommendations will emphasize more accurate weight-based dosages with less emphasis on age-based recommendations. 3. A standard system of using ml measurements only is being recommended. 4. Later this year, manufacturers will no longer manufacture the infant drop formulation (80mg/0.8ml) and will only market the children's formulation (160mg/5ml, which is much less concentrated that the infant drops). 5. Consideration will be given to marketing only one strength of children's tablet formulation.